American Journal of Kidney Diseases
Volume 55, Issue 5 , Pages 957-961 , May 2010

Lack of Toxic Effects of Methanol in a Patient With HIV

  • Marc Ghannoum, MD

      Affiliations

    • Division of Nephrology, Verdun Hospital, University of Montreal, Montreal, Canada
    • Corresponding Author InformationAddress correspondence to Marc Ghannoum, MD, Verdun Hospital, 4000 Lasalle Blvd, Verdun, Que, Canada, H4G 2A3
    • ,
  • Henri Kamal Haddad, MD

      Affiliations

    • Division of Nephrology, Verdun Hospital, University of Montreal, Montreal, Canada
    • ,
  • Valery Lavergne, MD

      Affiliations

    • Division of Infectious Diseases, Sacré-Coeur Hospital, University of Montreal, Montreal, Canada
    • ,
  • Jennifer Heinegg, MD

      Affiliations

    • Division of Nephrology, Verdun Hospital, University of Montreal, Montreal, Canada
    • ,
  • Jacques Jobin, MD

      Affiliations

    • Division of Nephrology, Verdun Hospital, University of Montreal, Montreal, Canada
    • ,
  • Mitchell L. Halperin, MD

      Affiliations

    • Division of Nephrology, St Michaels Hospital, University of Toronto, Toronto, Canada

Received 30 August 2009 ,Accepted 12 November 2009.

References 

  1. Oh M, Halperin ML. Toxin-induced metabolic acidosis. In:  Gennari FJ,  Adrogue HJ,  Galla JH,  Madias NE editor. Acid-Base Disorders and Their Treatment. Boston, MA: Marcel Decker Inc; 2005;p. 376–409
  2. Brent J, McMartin K, Phillips S, et al. Fomepizole for the treatment of ethylene glycol poisoning (Methylpyrazole for Toxic Alcohols Study Group). N Engl J Med. 1999;340(11):832–838
  3. Barceloux DG, Bond GR, Krenzelok EP, Cooper H, Vale JA. American Academy of Clinical Toxicology practice guidelines on the treatment of methanol poisoning. J Toxicol Clin Toxicol. 2002;40(4):415–446
  4. Roeggla G, Wagner A, Frossard M, Roeggla H. Marked variability in methanol toxicity. Am Fam Physician. 1993;48(5):731
  5. Kostic MA, Dart RC. Rethinking the toxic methanol level. J Toxicol Clin Toxicol. 2003;41(6):793–800
  6. Osterloh JD, Pond SM, Grady S, Becker CE. Serum formate concentrations in methanol intoxication as a criterion for hemodialysis. Ann Intern Med. 1986;104(2):200–203
  7. Jacobsen D, McMartin KE. Antidotes for methanol and ethylene glycol poisoning. J Toxicol Clin Toxicol. 1997;35(2):127–143
  8. Keyvan-Larijarni H, Tannenberg AM. Methanol intoxication (Comparison of peritoneal dialysis and hemodialysis treatment). Arch Intern Med. 1974;134(2):293–296
  9. d'Alessandro A, Osterloh JD, Chuwers P, Quinlan PJ, Kelly TJ, Becker CE. Formate in serum and urine after controlled methanol exposure at the threshold limit value. Environ Health Perspect. 1994;102(2):178–181
  10. Megarbane B, Borron SW, Trout H, et al. Treatment of acute methanol poisoning with fomepizole. Intensive Care Med. 2001;27(8):1370–1378
  11. Brent J, Lucas M, Kulig K, Rumack BH. Methanol poisoning in a 6-week-old infant. J Pediatr. 1991;118(4 pt 1):644–646
  12. Brent J, McMartin K, Phillips S, Aaron C, Kulig K. Fomepizole for the treatment of methanol poisoning. N Engl J Med. 2001;344(6):424–429
  13. Brown MJ, Shannon MW, Woolf A, Boyer EW. Childhood methanol ingestion treated with fomepizole and hemodialysis. Pediatrics. 2001;108(4):1–3
  14. Ekins BR, Rollins DE, Duffy DP, Gregory MC. Standardized treatment of severe methanol poisoning with ethanol and hemodialysis. West J Med. 1985;142(3):337–340
  15. Kerns W, Tomaszewski C, McMartin K, Ford M, Brent J. Formate kinetics in methanol poisoning. J Toxicol Clin Toxicol. 2002;40(2):137–143
  16. Hantson P, Mahieu P. Pancreatic injury following acute methanol poisoning. J Toxicol Clin Toxicol. 2000;38(3):297–303
  17. Pikkarainen PH, Raiha NC. Development of alcohol dehydrogenase activity in the human liver. Pediatr Res. 1967;1(3):165–168
  18. Parlesak A, Billinger MH, Bode C, Bode JC. Gastric alcohol dehydrogenase activity in man: influence of gender, age, alcohol consumption and smoking in a caucasian population. Alcohol Alcohol. 2002;37(4):388–393
  19. Vidal F, Perez J, Morancho J, Pinto B, Richart C. Hepatic alcohol dehydrogenase activity in alcoholic subjects with and without liver disease. Gut. 1990;31(6):707–711
  20. Ricciardi BR, Saunders JB, Williams R, Hopkinson DA. Hepatic ADH and ALDH isoenzymes in different racial groups and in chronic alcoholism. Pharmacol Biochem Behav. 1983;18(suppl 1):61–65
  21. Yuen GJ, Weller S, Pakes GE. A review of the pharmacokinetics of abacavir. Clin Pharmacokinet. 2008;47(6):351–371
  22. Walsh JS, Reese MJ, Thurmond LM. The metabolic activation of abacavir by human liver cytosol and expressed human alcohol dehydrogenase isozymes. Chem Biol Interact. 2002;142(1-2):135–154
  23. McDowell JA, Chittick GE, Stevens CP, Edwards KD, Stein DS. Pharmacokinetic interaction of abacavir (1592U89) and ethanol in human immunodeficiency virus-infected adults. Antimicrob Agents Chemother. 2000;44(6):1686–1690
  24. Peterson CD. Oral ethanol doses in patients with methanol poisoning. Am J Hosp Pharm. 1981;38(7):1024–1027
  25. Izzedine H, Launay-Vacher V, Aymard G, Legrand M, Deray G. Pharmacokinetics of abacavir in HIV-1-infected patients with impaired renal function. Nephron. 2001;89(1):62–67
  26. Hovda KE, Jacobsen D. Expert opinion: fomepizole may ameliorate the need for hemodialysis in methanol poisoning. Hum Exp Toxicol. 2008;27(7):539–546

 Originally published online as doi:10.1053/j.ajkd.2009.11.020 on February 22, 2010.

PII: S0272-6386(09)01652-7

doi: 10.1053/j.ajkd.2009.11.020

American Journal of Kidney Diseases
Volume 55, Issue 5 , Pages 957-961 , May 2010

Article Tools

* Image Usage & Resolution